Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers - 10/09/17
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
The allopurinol dose is limited in chronic kidney disease, particularly stage 4/5 chronic kidney disease. Febuxostat has a hepatic metabolism and has been approved without dose adaptation in gouty patients with stage 1–3 chronic kidney disease. We aimed to study the safety and efficacy of febuxostat for stage 4/5 chronic kidney disease.
Methods |
In this retrospective study, we included patients with (1) a diagnosis of gout, (2) febuxostat treatment, (3) estimated glomerular filtration rate≤30mL/min/1.73m2 (Modification of Diet in Renal Disease formula) at febuxostat initiation and (4) follow-up for at least 3 months after febuxostat initiation. Efficacy, safety and variation in estimated glomerular filtration rate were analyzed.
Results |
We included 73 patients (mean age 70.2±11.8, 61 men, 31 with vascular chronic kidney disease and 18 renal transplantation) with gout (baseline serum uric acid level=9.86±2.85mg/dL, mean gout duration 6.2±7.0 years) from 10 academic centers. Comorbidities included cardiac failure (17.8%), hypertension (98.6%), diabetes mellitus (30.1%), dyslipidemia (64.8%) and history of cardiovascular events (38.4%). At the last visit (mean follow-up 68.5±64.8 weeks), the daily dose of febuxostat was 40mg for 7 patients (10.5%), 80mg for 50 (74.6%) and 120mg for 10 (14.9%). Serum uric acid level was<6mg/dL for 49 patients (67%). Renal function improved for 18 patients, was unchanged for 24 and worsened for 31; 19 patients experienced flares and 1 patient, limb edema.
Conclusion |
Febuxostat seemed efficient in gouty patients with stage 4/5 chronic kidney disease. However, safety data were not clear regarding renal function. Larger studies are needed to assess safety.
Le texte complet de cet article est disponible en PDF.Keywords : Gout, Febuxostat, Chronic kidney disease
Plan
Vol 84 - N° 5
P. 595-598 - octobre 2017 Retour au numéro
Article précédent
- Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus
- Olivia Weill, Stéphane Decramer, Christophe Malcus, Behrouz Kassai, Isabelle Rouvet, Tiphanie Ginhoux, Yanick J. Crow, Fredéric Rieux-Laucat, Pauline Soulas-Sprauel, Anne Pagnier, Isabelle Koné-Paut, Maryam Piram, Caroline Galeotti, Charlotte Samaille, Héloïse Reumaux, Aurélia Lanteri, Sandrine Morell Dubois, Hélène Lefebvre, Stéphane Burtey, François Maurier, Aurélia Carbasse, Irène Lemelle, Ulrich Meinzer, Véronique Despert, Hugues Flodrops, Nicole Fabien, Bruno Ranchin, Eric Hachulla, Brigitte Bader-Meunier, Alexandre Belot
- Ultrasound abnormalities in septic arthritis are associated with functional outcomes
- Emeline Gaigneux, Grégoire Cormier, Stéphane Varin, Oriane Mérot, Yves Maugars, Benoit Le Goff
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?